Drugs / Ad5-nCoV
Ad5-nCoV
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04552366 | Sep → Dec 2020 | COVID-19 | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Completed | No outcome recorded |
| Phase 1 | NCT04568811 | Sep → Oct 2020 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT05043259 | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | Met primary |
| Phase 1/2 | NCT04840992 | Apr 2021 → Jul 2022 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04398147 | Aug 2020 → Dec 2021 | COVID-19 | CanSino Biologics Inc. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05293223 | Oct 2021 → Nov 2022 | — | Fundación Huésped | Completed | No outcome recorded |
| Phase 2 | NCT05005156 | Jun 2021 → Jan 2023 | COVID-19 | Fundación Huésped | Completed | No outcome recorded |
| Phase 2 | NCT04566770 | Sep 2020 → Sep 2021 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT05442684 | Nov 2022 → Mar 2023 | COVID-19 | CanSino Biologics Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT05169008 | Feb 2022 → Jan 2023 | COVID-19 | CanSino Biologics Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05204589 | Jan → Apr 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT04526990 | Sep 2020 → Aug 2021 | COVID-19 | CanSino Biologics Inc. | Completed | Met primary |
| Phase 3 | NCT04540419 | Sep 2020 → Jun 2021 | COVID-19 | NPO Petrovax | Completed | Met primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT05855408 | May 2023 → May 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT05303584 | Apr → Jun 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05313646 | Mar → Apr 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | Met primary |
| Phase not applicable2 trials · 2 met primary | ||||||
| — | NCT05886790 | May → Dec 2023 | COVID-19 | Zhongnan Hospital | Unknown | Met primary |
| — | NCT04916886 | Jun 2021 → Jul 2022 | COVID-19 | CanSino Biologics Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | CanSino Biologics Inc. | Regulatory COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing cansinotech.com ↗
Tianjin, May 19, 2022 – CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced that the World Health Organization (“WHO”) has granted Emergency Use Listing (“EUL”) for Convidecia™ |
| 2022-03-22 | CanSino Biologics Inc. | Regulatory CanSinoBIO's Convidecia Approved as Heterologous Booster in Malaysia and Indonesia cansinotech.com ↗
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Ministry of Health Malaysia ("MOH Malaysia") and the Indonesian National Agency of Drug and Food Control ("BPOM") as a heterologous booster. |
| 2022-03-14 | CanSino Biologics Inc. | Results Latest Study Shows Advantages of CanSinoBIO’s Convidecia as Heterologous Booster against Omicron Variant cansinotech.com ↗
The results showed that booster vaccination with either intramuscular injection or inhaled version of Convidecia generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster. |
| 2022-02-20 | CanSino Biologics Inc. | Regulatory Convidecia Approved as Heterologous Booster in China cansinotech.com ↗
its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™) has been approved by the Joint Prevention and Control Mechanism of the State Council of China (“State Council”) as a heterologous booster |
| 2021-12-23 | CanSino Biologics Inc. | Results Convidecia™ Phase III Results Published in The Lancet cansinotech.com ↗ |
| 2021-09-18 | CanSino Biologics Inc. | Results “Invisible Mask” for COVID Protection: Globally Innovative Inhaled Vaccine is Safer, More Effective and More Accessible cansinotech.com ↗
According to clinical trial data published in the medical journal The Lancet in July 2021, one dose of inhaled COVID-19 vaccine, Ad5-nCoV, can induce strong humoral, cellular and mucosal immunity without any severe vaccine-related adverse effects. |
| 2021-08-27 | Guangzhou Saliai Stem Cell Science and Technology Co. Ltd. | Results 喜报丨赛莱拉干细胞与院士团队合作在Nature子刊发表新冠疫苗的功效机制研究论文 saliai.com ↗
这项研究揭示了在接种疫苗后受试者细胞免疫增强，细胞免疫协同和细胞类型特异性 IFN 反应以及SARS-CoV-2特异性抗体的体液免疫。 |
| 2021-08-11 | NPO Petrovax | Results Phase III Immunogenicity and Safety Clinical Trial of Convidecia Vaccine Completed in Russia petrovax.com ↗
The Convidecia COVID-19 vaccine has demonstrated high immunogenicity and safety in the local Phase III clinical trial in Russia. |
| 2021-02-25 | CanSino Biologics Inc. | Regulatory CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine in China cansinotech.com ↗ |
| 2021-02-24 | CanSino Biologics Inc. | Regulatory NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO’s COVID-19 Vaccine ConvideciaTM cansinotech.com ↗
NMPA has accepted the application. |
| 2021-02-05 | NPO Petrovax | Results Independent International Committee Confirms that the Ad5-nCoV (Convidecia) Vaccine Complies with Previously Specified Safety and Efficacy Criteria petrovax.com ↗
Petrovax is pleased to announce that on February 1, the Independent Data Monitoring Committee (IDMC) confirmed that the Ad5-nCoV (Convidecia) vaccine met its pre-specified primary safety and efficacy criteria initially specified within the framework of international Phase III clinical trial. |
| 2020-08-15 | NPO Petrovax | Regulatory PETROVAX AND CANSINO BIOLOGICS ARE TO LAUNCH PHASE III INTERNATIONAL CLINICAL TRIAL OF THE POTENTIAL COVID-19 VACCINE IN RUSSIA petrovax.com ↗
Petrovax has obtained permission from the Russian Ministry of Health to conduct a phase III clinical trial of the Chinese vaccine candidate Ad5-nCov in Russia. |
| 2020-03-17 | CanSino Biologics Inc. | Regulatory CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China cansinotech.com ↗
has been approved to enter into Phase 1 Clinical Trial. |
All press releases naming this drug 22 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-nCoV | “BACKGROUND: To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 ×...” PMID 36888640 ↗ Mar 202316“450 participants were enrolled and randomly assigned into three groups to be vaccinated with an aerosolized Ad5-vectored bivalent vaccine (wild-type and BA.5, Ad5-CoV5T), an...” PMID 40775215 ↗ Aug 2025 “Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a...” PMID 37432025 ↗ Jan 2023 “This is a phase IIb clinical trial to evaluate safety and immuogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years...” NCT04566770 ↗ “The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies.” PMID 34953526 ↗ Dec 2021 “We aimed to assess the safety and immunogenicity of a homologous booster dose of the recombinant adenovirus type 5-vectored coronavirus disease 2019 (COVID-19) vaccine (Ad5-nCoV).” PMID 38038866 ↗ Dec 2023 “An orally aerosolized adenovirus type-5 vector-based coronavirus disease 2019 (COVID-19) vaccine (Ad5-nCoV) has recently been authorized for boosting immunization in China.” PMID 37202147 ↗ Sep 2023 “12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration” NCT04398147 ↗ “receiving Ad5-nCoV (intramuscular injection)” NCT05169008 ↗ |
| Known as | Ad5-nCoV vaccine | “Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster.” NCT05855408 ↗ |
| Known as | Ad5-nCoV-IH | “heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV-IH) after two-dose priming with an inactivated SARS-CoV-2...” NCT05204589 ↗ |
| Known as | Ad5-nCoV/O | “Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster...” NCT05442684 ↗ |
| Known as | Ad5-nCoV/O-IH | “Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster...” NCT05442684 ↗ |
| Known as | aerosolised Ad5-nCoV | “BACKGROUND: Aerosolised Ad5-nCoV is one of the first licensed mucosal respiratory vaccine against SARS-CoV-2 in the world; however, the safety profile of this vaccine has not...” PMID 37352880 ↗ Jun 2023 |
| Known as | Aerosolized Ad5-nCoV | “Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc.” NCT05204589 ↗ |
| Known as | Convidecia | “Convidecia” NCT05313646 ↗ |
| Known as | recombinant adenovirus type-5 vectored COVID-19 vaccine | “Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a...” PMID 37432025 ↗ Jan 2023 |
| Known as | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | “Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)” NCT05005156 ↗ |
| Modality | Vaccine | “Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)” NCT04398147 ↗ |
| Route | Intramuscular | “Intramuscular administration” NCT04398147 ↗ |